Subscribe
blue-pills-drugs
Urusaurus / shutterstock.com
16 January 2017Big Pharma

English High Court refers Truvada SPC case to CJEU

The English High Court has referred a supplementary protection certificate (SPC) dispute over Truvada (emtricitabine/tenofovir) to Europe’s highest court, the Court of Justice of the European Union (CJEU).

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

More on this story

Big Pharma
AG opines on ‘thorny issue’ in Truvada SPC clash
25 April 2018   Advocate General Melchior Wathelet has advised the Court of Justice of the European Union on a case involving a supplementary protection certificate.
Big Pharma
French court knocks out Gilead Truvada SPC
4 June 2018   The Paris Court of First Instance has nullified a supplementary protection certificate covering Gilead’s HIV/AIDS treatment Truvada.
Big Pharma
CJEU clarifies ‘basic patent’ meaning in SPC dispute
25 July 2018   Earlier today, the Court of Justice of the European Union clarified when a product is ‘protected by a basic patent’ within the meaning of article 3(a) of the SPC regulation.

More features

Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages